Metformin Mechanisms in Diabetes Management

Metformin is the cornerstone of type 2 diabetes therapy worldwide, valued for its glucose-lowering efficacy, safety profile and affordability. Its primary action involves suppression of hepatic gluconeogenesis, thereby reducing endogenous glucose output. At the cellular level, metformin modulates energy metabolism through both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Key molecular targets include mitochondrial complex I, where metformin impairs electron transport, and mitochondrial glycerophosphate dehydrogenase, which together contribute to altered cellular redox balance. Emerging evidence highlights a lysosomal mechanism in which metformin binds to PEN2, inhibiting the v-ATPase proton pump and activating AMPK without major shifts in cellular AMP levels. Beyond hepatic effects, the gut has been recognised as a critical site of action: metformin influences intestinal glucose handling, alters bile acid reabsorption and reshapes the microbiome. Appetite regulation and systemic energy homeostasis are further modulated via circulating metabolites such as N-lactoyl phenylalanine. Collectively, these multifaceted interactions underpin metformin’s global impact on glycaemic control and its potential benefits in metabolic and age-related disorders.

Research from Nature Portfolio

Recent studies have demonstrated that clinically relevant metformin dosing elevates the appetite-suppressing metabolite N-lactoyl phenylalanine in both individuals with type 2 diabetes and healthy volunteers, offering a direct link between metformin administration and central regulation of food intake. Separately, work has revealed that metformin binds to the γ-secretase subunit PEN2 at micromolar concentrations, forming a complex with ATP6AP1 to inhibit lysosomal v-ATPase. This interaction triggers local activation of AMPK, leading to reductions in hepatic lipid accumulation and improvements in glycaemic control in animal models with tissue-specific PEN2 deletion. These findings identify PEN2 as a direct molecular target and underscore a lysosomal signalling route critical to metformin’s therapeutic actions.

Metformin Mechanisms in Diabetes Management publication trend

The graph below shows the total number of articles in metformin mechanisms in diabetes management across all publications each year (not limited to Nature Index journals).

Technical terms

AMPK (AMP-activated protein kinase): An energy sensor kinase that regulates nutrient and energy balance, central to metformin’s metabolic effects.

Gluconeogenesis: The biochemical pathway by which the liver produces glucose from non-carbohydrate precursors, a principal target of metformin.

v-ATPase (lysosomal proton pump): A proton-transporting enzyme in lysosomes; its inhibition by metformin–PEN2 complex activates AMPK via a lysosomal axis.

Redox balance: The homeostatic equilibrium of reduction–oxidation reactions within cells, modulated by metformin to influence energy metabolism.

Lac-Phe (N-lactoyl phenylalanine): A circulating metabolite shown to suppress appetite, elevated in response to metformin treatment.

References

1. Metformin and feeding increase levels of the appetite-suppressing metabolite Lac-Phe in humans. Nature Metabolism (2024).
2. Low-dose metformin targets the lysosomal AMPK pathway through PEN2. Nature (2022).
3. The mechanisms of action of metformin. Diabetologia (2017).
4. Metformin and the gastrointestinal tract. Diabetologia (2016).
5. Cellular and Molecular Mechanisms of Metformin Action. Endocrine Reviews (2020).